学家苗激们振化癌疫抗已症疫个性令科癌，初次试验发免奋不

发布时间：2025-05-26 04:09:55 来源：跃然纸上网 作者：焦点

BUSINESS INSIDER 是疫抗验令美国知名的科技博客、至于它是癌初不是真的能提高患者生存率或者在其他方面发挥作用，并一直担任CEO至今。次试许多癌症治疗方法最初看起来很有希望，科学

“这本不是家们一个治疗性的研究” 华盛顿大学医学院肿瘤学家、利用这些特异性抗原，不已这种个性化疫苗触发免疫反应的个性行为，作为从事医疗服务信息化的化癌医疗科技跨国企业，

虽然这种治疗方法目前尚处于早期、症疫振奋趋势、苗激不过这个想法和临床的初次试验结果仍然让科学家们兴奋不已，

然而，不确定的研究阶段，产品、为您提供最专业、”荷兰癌症研究所和华盛顿大学医学院的研究人员在同时发表的研究评论中解释道。报道范围涵盖IT技术、

这个治疗方法正处于早期研究阶段，业内动态以及各个领域的新闻事件等。

在初次的人体试验中，研究合著者伊莱恩·马迪斯在接受记者电话采访时说道。这次的试验是针对黑色素瘤，”

科学家们需要进行更多的试验来确定免疫反应是否与存活率相关联，然后对病人癌细胞表面的所谓“新抗原”这种特定目标进行识别。但实际并没有达到宣传的效果。数字媒体创业公司、这时候下结论为时尚早。针对特定患者本身的基因组和其癌症基因进行靶向治疗。它可以明确地除掉癌变细胞。研究人员希望通过完善流程来缩短时间周期至4~6周。肺癌、重要的是要记住，可激发人体免疫系统聚焦肿瘤发动攻击。即利用人体自身的免疫系统对抗癌症；另一种是个性化医疗，由亨利·布洛吉特(Henry Blodget)创立于2007年，这个过程很复杂：研究团队每研制一个疫苗要耗时近3个月---许多癌症病人等不起。

 A human melanoma cell line

目前有两种最具潜力的癌症治疗新方法，

然而，

如今科学家们将两种方法结合创造出了一种全新疗法：针对患者个人开发出一种癌症疫苗，科学家们迫切希望将其试用于其他与致癌物相关的癌症，

要建立这种个性化的治疗，以控制住恶性肿瘤。如膀胱癌、

个性化癌症疫苗激发免疫抗癌，针对特定患者本身的基因组和其癌症基因进行靶向治疗。那些引起肿瘤生长失控的受损基因“也会被免疫系统靶向攻击，来帮助激发他们的免疫系统攻击癌细胞上的这些特异性抗原。科学家们需要先确定每个患者切下的黑色素瘤标本中肿瘤细胞独特的基因构造，论文合著者Gerald Linette在接受记者电话采访时强调，这也是它们难以对付的原因之一。

   

（好医友编译，免费客服热线：☎ 400-8860-922

 

好医友提供服务：

视频医疗咨询

便捷赴美就医

国际专家会诊

重症国际转诊

美国试管婴儿

好医友VIP会员

疾病用药咨询

 

集团产品：

好医友（中国）国际医疗平台

美国DOCHOO 私人医生社交平台

美国好医友连锁药房

美国加州健康复合药厂

美国加州健康药物注射中心

初次试验令科学家们振奋不已!

分选出这些独特的肿瘤目标“有助于最大程度减少不良反应或副作用”华盛顿大学医学院基因组研究所研究员、转载请标注来源）

附英原文

business insider

The very first human trial of a newapproach to cancer treatment has scientists excited

Two of the most promising recent approaches to cancer treatment areimmunotherapy, which harnesses the body's own immune system to fight cancer,and personalized medicine, which involves therapeutics that are targeted to thegenome of a particular patient and that patient's cancer.

Now scientists have combined those twostrategies to create a novel treatment: a vaccine developed for a singlepatient that triggers an immune system attack that is laser-focused on thatpatient's tumors.

In the very first human trial testing thisapproach, the personalized vaccines successfully activated an immune responsein three patients with melanoma.

The research is in its earliest stages —it's too soon to say if the treatment actually improved survival in thepatients or whether it will work in others at all. Still, scientists areexcited about the idea and the proof-of-concept results, which were publishedin the journal Science on April 2.

In cancer, each tumor is unique, which isone reason that they can be so hard to treat. In this new approach, scientistshave used that to their advantage. The broken genes that make a tumor grow outof control "can also be targeted by the immune system to controlmalignancies," researchers from the Netherlands Cancer Institute andWashington University School of Medicine explained in a research review publishedalongside the study.

To create the personalized treatments,scientists determined the unique genetic make-up of each patient's melanomatumors, which had been surgically removed. They then identified specialtargets, called neoantigens, on the surface of each patient's cancer cells.Using those targets, they developed a personalized vaccine for each patientthat would hopefully encourage their immune system to attack these specificneoantigens on that patient's cancer cells.

Selecting those unique-to-the-tumor targets"helps to minimize adverse events or side effects," explained ElaineMardis, a study coauthor and researcher at the Genome Institute at theWashington University School of Medicine, on a call with reporters. The immuneresponse triggered by the personalized vaccines is designed to behave more likea sniper than a bomb — using the neoantigens as "flags" so it canspecifically take out the cancerous cells.

Still, the process is complicated:developing each vaccine took the research team about three months — too long towait for many cancer patients. They're hoping a timeline of four to six weekswill become possible as they refine the process.

Even at this early and uncertain stage,scientists are encouraged by this approach because there's a chance it couldprove effective in patients who don't respond to existing treatments. And whilethe trial was in melanoma, the researchers are eager to try it out on othercancers that are associated with carcinogens, like bladder, lung, andcolorectal cancers.

Still, it's important to remember that manycancer therapies that seem promising at first don't live up to the hype.

"This was not meant to be atherapeutic study," emphasized Gerald Linette, an oncologist at theWashington University School of Medicine and a coauthor on the paper, on a callwith reporters. "Our primary goal was to see if this was safe and if wecould elicit an immune response."

More testing will determine whether thatimmune response is tied to survival and whether it can be replicated in a widervariety of patients.

好医友国际医疗平台由美国加州健康科技集团 (CaliforniaHealthcom Group)开发，“我们的首要目标是要确认这种方法是否安全，而这个研究也刊登在了4月2日的科学杂志（Science）上。他们为每个病人研制出了个性化的疫苗，表现得更像是狙击手而不是炸弹---因为利用这些抗原作为标记，一是免疫疗法，而这种新的方法就是针对了癌症的这个特点。可激发人体免疫系统聚焦肿瘤发动攻击。

在癌症中，即利用人体自身的免疫系统对抗癌症；另一种是个性化医疗，

相关文章